Home / World Marketplace / Global Corporate Affairs / Archive by category Survey and Research (Page 52)

Archive by category Survey and Research

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

SHANGHAI, Sept. 24, 2024 (Korea Bizwire) – Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its wholly-owned subsidiary, TopAlliance Biosciences Inc. (TopAlliance Biosciences), announce that the European Commission (EC) has approved toripalimab (European trade name: LOQTORZI®) [...]

Quantexa Recognized as a Leader in IDC MarketScape for Worldwide Decision Intelligence Platforms 2024

Independent Assessment Highlights Quantexa’s Data Unification, AI, and Scalability Capabilities LONDON, Sept. 24, 2024 (Korea Bizwire) – Quantexa, the global leader in Decision Intelligence (DI) solutions for the public and private sectors, has been recognized as a Leader in the IDC MarketScape: Worldwide Decision Intelligence Platforms 2024 Vendor Assessment (doc # US51047423, August 2024). IDC defines Decision Intelligence Platforms [...]

BankNewport Reports Deposit Account Opening Process Accelerated by as much as Ninety Percent, Streamlining a Key Consumer Banking Experience with nCino

Rhode Island-based community bank sees digital account opening process considerably reduced and cuts in-branch account opening time with nCino Consumer Deposit Account Opening WILMINGTON, N.C., Sept. 24, 2024 (Korea Bizwire) – nCino, Inc. (NASDAQ: NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced that BankNewport is live on the nCino Platform. Since selecting nCino as a [...]

Medical devices, SMEs in healthcare: 4,000 companies at risk of default due to new tax – reports LaPresse

ROME, Sept. 23, 2024 (Korea Bizwire) – “In Italy, a regulation imposing a large tax threatens 4,000 companies that supply hospitals and healthcare facilities with essential medical devices, ranging from gauze to syringes, heart valves, coronary stents, and femur prosthetics—devices crucial for treating patients. For 2,000 of these companies, the tax, called ‘payback,’ is essentially a [...]

Intesa Sanpaolo is the World’s Leading Bank for Diversity and Inclusion in the 2024 “Ftse Diversity & Inclusion Index – Top 100”

Ranking seventh globally among the top 100 companies, Intesa Sanpaolo is the only Italian bank in the FTSE Russell index MILAN and TURIN, Italy, Sept. 23, 2024 (Korea Bizwire) – Intesa Sanpaolo has been ranked the world’s leading bank among the 100 most inclusive and diversity-sensitive workplaces in the FTSE Diversity & Inclusion Index – Top 100, the [...]

Jackson Health System projects 47% reduction in carbon emissions from patient monitors with Philips next generation monitoring platform

Opportunity for significant savings in energy consumption, reduction of paper and elimination of disposable batteries for telemetry revealed in Life Cycle Assessment Amsterdam, The Netherlands and Cambridge, Mass. and Miami, FL. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Jackson Health System, one of the nation’s largest public health systems in [...]

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder2,3 Data presented at the European [...]

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome (PDSS) New Phase 3 SOLARIS and Phase 1 safety data show no incidence of PDSS in study participants receiving TEV-‘749 [...]

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPs New data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identified New ADVANCE survey findings highlight key patient-reported [...]

CertiK Engineer Recognized for Identifying Vulnerability in Apple Vision Pro’s Eye-Tracking Technology

NEW YORK, Sept. 20, 2024 (Korea Bizwire) – CertiK, the industry-leading Web3 security firm, is proud to announce that Haoqi Shan, a distinguished member of CertiK’s engineering team, has been recognized for his critical role in identifying a vulnerability in Apple’s Vision Pro mixed reality headset. The findings, conducted in collaboration with five other computer [...]